Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM42B0C)

Drug Name
BMS-986253 Drug Info
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM42B0C

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN interleukin 8 (IL8) TT3JF7X IL8_HUMAN Inhibitor [1]
Interleukin-8 (IL8) TTCTE1G IL8_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-8 (IL8) DTT CXCL8 4.892 4.17 4.65 3.807
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-8 (IL8) DTT CXCL8 9.05E-17 2.09 3.08
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.
3 Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.